| [1] |
GOWER E, ESTES C, BLACH S, et al. Global epidemiology and genotype distribution of the hepatitis C virus infection[J]. J Hepatol, 2014, 61(1 Suppl): s45-s57. DOI: 10.1016/j.jhep.2014.07.027. |
| [2] |
Polaris Observatory HCV Collaborators. Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study[J]. Lancet Gastroenterol Hepatol, 2022, 7(5): 396-415. DOI: 10.1016/S2468-1253(21)00472-6. |
| [3] |
Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association. Guideline for the prevention and treatment of hepatitis C (2022 version)[J]. Chin J Clin Infect Dis, 2022, 15(6): 428-447. DOI: 10.3760/cma.j.issn.1674-2397.2022.06.002. |
| [4] |
European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C: Final update of the series☆[J]. J Hepatol, 2020, 73(5): 1170-1218. DOI: 10.1016/j.jhep.2020.08.018. |
| [5] |
ZENG QL, ZHANG JY, ZHANG Z, et al. Sofosbuvir and ABT-450: terminator of hepatitis C virus?[J]. World J Gastroenterol, 2013, 19(21): 3199-3206. DOI: 10.3748/wjg.v19.i21.3199. |
| [6] |
ZHU SS, ZENG QL, DONG Y, et al. Interferon- α plus ribavirin yields 98% sustained virologic response in children aged 1-5 years with iatrogenic chronic hepatitis C[J]. Hepatol Int, 2015, 9(4): 578-585. DOI: 10.1007/s12072-015-9671-8. |
| [7] |
SPERA AM, ELDIN TK, TOSONE G, et al. Antiviral therapy for hepatitis C: Has anything changed for pregnant/lactating women?[J]. World J Hepatol, 2016, 8(12): 557-565. DOI: 10.4254/wjh.v8.i12.557. |
| [8] |
ABDALLAH M, ALBORAIE M, ABDEL-RAZEK W, et al. Pregnancy outcome of anti-HCV direct-acting antivirals: Real-life data from an Egyptian cohort[J]. Liver Int, 2021, 41(7): 1494-1497. DOI: 10.1111/liv.14913. |
| [9] |
ZENG QL, YU ZJ, LV J, et al. Sofosbuvir-based therapy for late pregnant women and infants with severe chronic hepatitis C: A case series study[J]. J Med Virol, 2022, 94(9): 4548-4553. DOI: 10.1002/jmv.27877. |
| [10] |
BHATTACHARYA D, ARONSOHN A, PRICE J, et al. Hepatitis C Guidance 2023 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection[J]. Clin Infect Dis, 2023. DOI: 10.1093/cid/ciad319.[Online ahead of print] |
| [11] |
GAO X, JI FP. Diagnosis and treatment strategies of hepatitis C-related hepatocellular carcinoma in the era of direct-acting antiviral drugs[J]. Chin J Hepatol, 2020, 28(10): 827-830. DOI: 10.3760/cma.j.cn501113-20200914-00516. |
| [12] |
REIG M, CABIBBO G. Antiviral therapy in the palliative setting of HCC (BCLC-B and -C)[J]. J Hepatol, 2021, 74(5): 1225-1233. DOI: 10.1016/j.jhep.2021.01.046. |
| [13] |
MOCAN T, NENU I, CRǍCIUN R, et al. Treatment of hepatitis C virus infection in patients with hepatocellular carcinoma: Truth or dare?[J]. J Gastroenterol Hepatol, 2021, 36(6): 1518-1528. DOI: 10.1111/jgh.15376. |
| [14] |
WAZIRY R, HAJARIZADEH B, GREBELY J, et al. Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: A systematic review, meta-analyses, and meta-regression[J]. J Hepatol, 2017, 67(6): 1204-1212. DOI: 10.1016/j.jhep.2017.07.025. |
| [15] |
JI F, YEO YH, WEI MT, et al. Sustained virologic response to direct-acting antiviral therapy in patients with chronic hepatitis C and hepatocellular carcinoma: A systematic review and meta-analysis[J]. J Hepatol, 2019, 71(3): 473-485. DOI: 10.1016/j.jhep.2019.04.017. |
| [16] |
PRENNER SB, VANWAGNER LB, FLAMM SL, et al. Hepatocellular carcinoma decreases the chance of successful hepatitis C virus therapy with direct-acting antivirals[J]. J Hepatol, 2017, 66(6): 1173-1181. DOI: 10.1016/j.jhep.2017.01.020. |
| [17] |
SINGAL AG, RICH NE, MEHTA N, et al. Direct-acting antiviral therapy for hepatitis C virus infection is associated with increased survival in patients with a history of hepatocellular carcinoma[J]. Gastroenterology, 2019, 157(5): 1253-1263. e2. DOI: 10.1053/j.gastro.2019.07.040. |
| [18] |
DANG H, YEO YH, YASUDA S, et al. Cure with interferon-free direct-acting antiviral is associated with increased survival in patients with hepatitis C virus-related hepatocellular carcinoma from both East and West[J]. Hepatology, 2020, 71(6): 1910-1922. DOI: 10.1002/hep.30988. |
| [19] |
JI F, LI T, NGUYEN MH. Improved survival and high sustained virologic response with DAA therapy in patients with HCV-related HCC: A call for expanded use[J]. J Gastroenterol Hepatol, 2021, 36(6): 1721-1722. DOI: 10.1111/jgh.15420. |
| [20] |
KUDO M, FINN RS, QIN S, et al. Overall survival and objective response in advanced unresectable hepatocellular carcinoma: A subanalysis of the REFLECT study[J]. J Hepatol, 2023, 78(1): 133-141. DOI: 10.1016/j.jhep.2022.09.006. |
| [21] |
REN Z, QIN S, MENG Z, et al. A phase 2 study of camrelizumab for advanced hepatocellular carcinoma: Two-year outcomes and continued treatment beyond first RECIST-defined progression[J]. Liver Cancer, 2021, 10(5): 500-509. DOI: 10.1159/000516470. |
DownLoad: